AAVogen is a company founded in 2018 headquartered in the United States. Its most recent tracked round is Pre-Seed. Brouky records 1 investor associated with the company.
AAVogen develops gene therapeutics for muscle wasting diseases such as inclusion body myositis, Duchenne muscular dystrophy, and heart failure, using muscle-specific AAV vectors to build muscle mass and strength.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.